The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study

for GUSTA trial study group, Barbara Rossetti, Roberta Gagliardini, Gaetana Sterrantino, Vincenzo Colangeli, Alessandra Latini, Manuela Colafigli, Francesca Vignale, Stefano Rusconi, Antonio Di Biagio, Giancarlo Orofino, Ivano Mezzaroma, Vincenzo Vullo, Daniela Francisci, Claudio Mastroianni, Michele Trezzi, Benedetta Canovari, Silvia Lamonica, Arturo Ciccullo, Alberto BorghettiAntonella DʼArminio Monforte, Simona Di Giambenedetto, Andrea De Luca

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)e17-e21
JournalJournal of Acquired Immune Deficiency Syndromes
Volume81
Issue number1
DOIs
Publication statusPublished - May 1 2019

Cite this

group, F. GUSTA. T. S., Rossetti, B., Gagliardini, R., Sterrantino, G., Colangeli, V., Latini, A., Colafigli, M., Vignale, F., Rusconi, S., Di Biagio, A., Orofino, G., Mezzaroma, I., Vullo, V., Francisci, D., Mastroianni, C., Trezzi, M., Canovari, B., Lamonica, S., Ciccullo, A., ... De Luca, A. (2019). The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. Journal of Acquired Immune Deficiency Syndromes, 81(1), e17-e21. https://doi.org/10.1097/QAI.0000000000001986